Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe

Novavax (NVAX) received a $125 million milestone payment from Sanofi as the latter initiated a Phase 3 trial for a combination influenza-COVID-19 vaccine in Europe. The trial combines Sanofi's high-dose flu vaccine with Novavax's Nuvaxovid COVID-19 vaccine. Novavax may earn additional milestones and royalties, including a $225 million payment upon a U.S. launch. The partnership has generated over $1 billion in revenue for Novavax to date, according to the company.

Original reporting
Published Oct 29, 2026, 1:37 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 1:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe — source image
Decision brief

The 30-second read

$NVAXBullishMed
01

Why it matters

The payment confirms the commercial viability of Novavax's COVID‑19 platform and may lead to additional royalty streams, supporting the stock.

02

Market read

First‑report milestone payment provides fresh, material cash flow information for NVAX, likely influencing short‑term price action.

03

What to watch

The $75 M future milestone tied to technology transfer in 2027 and a $225 M U.S. launch milestone could drive longer‑term valuation beyond the immediate cash receipt.

Relevance 8/10Novelty 8/10Timing: today

Background

Novavax announced a $125 M milestone from Sanofi after the initiation of a Phase 3 trial for a combined flu‑COVID‑19 vaccine in Europe, underscoring the partnership's revenue potential.

Company-level read

Ticker impact

$NVAXBullishHigh confidence
Context

Novavax received a $125 million milestone payment from Sanofi after the fifth patient was dosed in the Phase 3 flu‑COVID‑19 combination trial.

Expected impact

likely upward pressure as investors price in the $125 M payment and future royalty potential

Evidence & confidence

Milestone payments are material cash events; the amount is sizable for a biotech and signals continued partnership revenue.

Market effects

Strengthens the flu‑COVID‑19 vaccine partnership narrative, potentially boosting sentiment for other biotech firms with similar collaborations.

May provide a modest lift to US biotech indices as the news is US‑listed and reflects ongoing vaccine development activity.

Highlights continued investment in combination vaccines, a trend of interest to global pharma investors.

Counterpoint

If the trial encounters safety or efficacy setbacks, the upfront milestone could be offset by future royalty risk, limiting upside.

Key entities

  • Novavax, Inc.

    US‑listed biotech developing the COVID‑19 vaccine Nuvaxovid.

  • Sanofi

    French pharma partner conducting the Phase 3 combination trial.

Related articles

$NVAXHighAI 8/10

Novavax (NVAX) stock trades up, here is why

Novavax (NVAX) shares rose 8.8% after reporting Q3 2026 revenue of $68M and raising its full-year revenue outlook to $400M midpoint. The company also received a $125M milestone payment. NVAX reported a net loss of $31M, narrower than the prior year's $202M loss. The stock is up 49.4% YTD but remains 16.9% below its 52-week high.

$NVAXMed

Novavax Q3 Earnings Call Highlights

Novavax reported Q3 revenue of $68M, down from $70M YoY, with a net loss of $31M, improved from a $202M loss last year. The company reduced expenses by 41% YoY and expects its cash runway to extend into 2029. Novavax plans to start clinical testing for its C. diff vaccine candidate in 2027 and is exploring oncology applications for its Matrix-M adjuvant. The company aims to reduce expenses to $150M-$200M by 2028.

$NVAXMed

Novavax (NVAX) Q3 2026 Earnings Call Transcript

Novavax (NVAX) reported Q3 2026 earnings, highlighting a $125 million milestone from Sanofi's phase III trial of a combination flu-COVID vaccine. The company expects additional milestones and revenue from partnerships. Novavax also plans to advance its C. diff vaccine candidate and expand into oncology. The company raised its full-year revenue outlook and improved expense guidance.